v28i2

–2023 2017 ✚ First study to show the increased risk of gastric cancer with longterm use of proton pump inhibitors ✚ First in Hong Kong to establish the Kidney Transplantation Across Immunological Barrier Programme for ABO-incompatible and HLA-sensitised patients, in collaboration with Haematology Service and Urology Kidney Transplantation Service at QMH ✚ First in Hong Kong to establish a formal Adult Immunology and Allergy Service ✚ 首次研究證實長期使用氫離子幫浦阻斷 劑會增加胃癌風險 ✚ 與瑪麗醫院血液科服務及泌尿科腎臟移 植專科服務合作,在本港率先為 ABO 血型不合及人類白血球抗原過敏患者建 立跨免疫屏障腎臟移植計劃 ✚ 設立本港首項成人免疫學及過敏服務 2019 Establishment of the combined Dermatology-Rheumatology Clinic 成立皮膚風濕科聯合診所 2020 COVID-19 patients received medical care and treatment in the isolation facilities and followed up at the Infectious Disease Clinic at QMH 新冠患者在隔離設施接受治療, 並於瑪麗醫院傳染病診所覆診 2021 ✚ Pioneered provision of CAR-T Cell Therapy for Acute Lymphoblastic Leukaemia and Diffuse Large B-cell Lymphoma in Hong Kong Introduction of GMP-grade Oral Arsenic Trioxide for the treatment of Acute Promyelocytic Leukaemia to QMH, HKU-Shenzhen Hospital and Hong Kong Children Hospital ✚ 首度引入CAR-T細胞療法,治療急性 淋巴性白血病和瀰漫性大型B細胞 淋巴瘤 於瑪麗醫院、港大深圳醫院及香港兒童 醫院引進良好生產規範(GMP)級別口服 三氧化二砷,治療急性早幼粒細胞白血病 2022 ✚ Pioneered the use bepirovirsen, the first anti-sense oligonucleotide, in the treatment of chronic hepatitis B Establishment of Lung Nodule Programme Establishment of the School of Clinical Medicine. The Department of Medicine became one of the 16 departments, centres and units. ✚ 率先使用首隻反義寡核苷酸 bepirovirsen治療慢性乙型肝炎 推出肺結節治療計劃 臨床醫學學院成立,內科學系成為學院 16個學系、學組和中心的一員 2023 HKUMed study showed the declining global prevalence of Helicobacter pylori over the past 40 years ✚ Establishment of HKUMed Laboratory of Cellular Therapeutics, the first GMP multi-products facility in Hong Kong with approval in principle from the HKSAR Department of Health for an ATP manufacturing license 100th Anniversary of the Department of Medicine 學院研究發現過去40年全球幽門螺旋桿菌 盛行率呈下降趨勢 ✚ 成立香港大學細胞治療實驗室,為本港 首個有GMP規範認證的多樣產品設施, 獲香港衞生署原則性批出製造先進療法 產品牌照 學系成立一百周年 25 HKUMed News Winter 2023

RkJQdWJsaXNoZXIy Mzg4NDg0